Kanabo Group
Plc
("Kanabo" or the
"Company")
Board
Changes
Kanabo Group plc (LSE: KNB), a
health tech company with digital health services and specialist
medicines, announces that Mr David
Tsur will be stepping down from the Board of Directors with
effect from 30 January
2025. Mr Tsur has served as a member of the Board since
Admission in early 2021 and held the position of Chairman for more
than 2 years. He has been part of the Kanabo journey since
2018.
Avihu Tamir, CEO of Kanabo,
commented:
"David has personally mentored me since the earliest days of Kanabo
and has been integral to some of our most significant achievements.
His wealth of experience, unwavering support, and commitment to our
mission have been invaluable not only to the Company but also to my
own journey. I extend my gratitude to David for everything he has
done for Kanabo, and I wish him the very best."
Mr
Ian Mattioli, Chairman of the Board of
Directors, said:
"On behalf of the entire Board, I would like to express our sincere
gratitude to David for his contributions to Kanabo. He has served
the Company professionally and committedly, and we are grateful for
his invaluable insights and guidance. We wish him all the best as
he embarks on new opportunities."
Kanabo further announces its
intention to appoint a new
UK-based Director to the Board. A separate announcement will
be made in due course.
Enquiries:
|
Kanabo Group plc
Avihu Tamir, Chief Executive
Officer
Ian Mattioli, Non-Executive Chair of
the Board
|
|
|
Peterhouse Capital Ltd (Financial Adviser)
Guy Miller / Lucy Williams / Charles
Goodfellow
|
+44 (0)20 7469 0930
|
About Kanabo Group plc
Kanabo Group plc (LSE: KNB) is a
digital health company committed to transforming patient care
through its innovative technology platform and specialised
treatment offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated
medicinal cannabis-derived formulations and therapeutic inhalation
devices.
Kanabo's NHS-approved online
telehealth platform, The GP Service, provides patients with video
consultations, online prescriptions, and primary care services.
Leveraging its telehealth capabilities, in February 2023, Kanabo
launched Treat-It, an online clinic focused on chronic pain
management that provides patients with secondary care. In June
2024, the Treat-It partnership was expanded to 14 other in-pharmacy
locations.
With its two complementary business
divisions, Kanabo has established itself as an end-to-end digital
health provider. It offers telehealth consultations, prescriptions
and tailor-made treatments.
The Company's partially owned
subsidiary, Kanabo Agritec Ltd, is a cultivation consultancy
supporting cannabis businesses in developing new farms through
infrastructural, research, and product guidance. These farms
deliver high-quality raw materials for Kanabo's formulas and
product line.
At Kanabo Group Plc, we are
dedicated to providing patients with the highest quality medical
treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com
for more
information.